Bortecad 2.5mg Injection contains Bortezomib, which is a proteasome inhibitor used in the treatment of certain types of cancers, most commonly multiple myeloma and mantle cell lymphoma. Bortezomib acts by preventing the breakdown of proteins by cell structures called proteasomes, which causes a buildup of proteins in cancer cells and ultimately results in their death.

Brand Name: Bortecad

Composition: Bortezomib

Mechanism of Action:

Proteases are important in the breakdown of proteins that control cell development, and boratezomib suppresses their action. Protease inhibition causes damaged proteins to accumulate in the cell, which kills cancer cells and slows the growth of tumors.

Uses:

• Multiple Myeloma
• Mantle Cell Lymphoma
• Waldenström's Macroglobulinemia
• Amyloidosis

Side Effects:

• Fatigue
• Weakness
• Nausea
• Fever
• Anemia
• Neutropenia
• Thrombocytopenia
• Numbness
• Rash
• Tumor Lysis Syndrome
• Herpes Zoster Reactivation

Dosage and Administration:

The dosage of Bortecad is typically based on body surface area and is administered as an injection either subcutaneously (under the skin) or intravenously (into a vein).

Safety Advise:

Liver  

Bortezomib can cause liver damage or elevate liver enzymes. Regular monitoring of liver function tests is advised. Kindly speak with your healthcare provider.

Lung  

Bortezomib can cause severe lung problems, including acute respiratory distress syndrome (ARDS) and interstitial lung disease. Kindly speak with your healthcare provider.

Pregnancy  

Bortezomib may cause harm to a developing fetus. Kindly speak with your healthcare provider.

Breastfeeding  

Bortecad 2.5 Injection is dangerous to use while breastfeeding. Evidence points to the possibility of medication poisoning in the fetus. Kindly speak with your healthcare provider.

Alcohol  

When used with alcohol, Bortecad 2.5 Injection may cause extreme sleepiness. Kindly speak with your healthcare provider.

Storage:

Store the injection vial at 2-8°C (36-46°F) in a refrigerator. Protect from light and do not freeze.

How to use this Medication?

Bortezomib is available as a liquid solution that can be injected subcutaneously (beneath the skin) or into a vein. In a clinic or doctor's office, a nurse or doctor administers boratezamib. The disease you have, the other medications you take, and how well your body reacts to treatment will all affect your dose plan.

Throughout your therapy, make sure to let your doctor know how you are feeling. If you have side effects from bortezomib, your doctor may temporarily halt your therapy or lower your dosage. 

References:

1.      Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discovery medicine. 2011 Dec;12(67):471.

2.      Paramore A, Frantz S. Bortezomib. Nature reviews Drug discovery. 2003 Aug 1;2(8):611-2.

3.      Scott K, Hayden PJ, Will A, Wheatley K, Coyne I. Bortezomib for the treatment of multiple myeloma. Cochrane Database of Systematic Reviews. 2016(4).

4.      Piperdi B, Ling YH, Liebes L, Muggia F, Perez-Soler R. Bortezomib: understanding the mechanism of action. Mol Cancer Ther. 2011 Nov 1;10(11):2029-30.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Cadila Pharmaceuticals Ltd

Address: Sarkhej-Dholka Road, Bhat, Ahmedabad-382 210, INDIA.

Country of origin: India